Company Overview of Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. develops therapies for the treatment of dyslipidemia and cardiovascular diseases. Its products include Epanova, an Omega 3 fatty acid that has completed Phase III clinical studies to treat patients with triglycerides. The company has a license agreement with Chrysalis Pharma AG to develop and commercialize Epanova; and an agreement with BioVectra Inc. for the manufacture of the active pharmaceutical ingredient for Epanova. Omthera Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Princeton, New Jersey. As of July 18, 2013, Omthera Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca LP.
707 State Road
Princeton, NJ 08540
Founded in 2008
Key Executives for Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|NSA International, Inc.||United States|
|Dual Therapeutics, LLC||United States|
|Altheus Therapeutics, Inc.||United States|
|ARIAD Gene Therapeutics, Inc.||United States|
|Tocagen Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Omthera Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.